PathAI

About

PathAI builds AI-powered image analysis tools specifically for pathology, offering products like their FDA Breakthrough Device designated algorithm for detecting minimal residual disease in breast cancer and their coreDSP platform for digital pathology workflow optimization. Their key innovation lies in applying deep learning to whole slide images, enabling more accurate and reproducible diagnosis, biomarker identification, and patient stratification in clinical trials. PathAI partners with leading pharmaceutical companies like Bristol Myers Squibb and Roche, and has secured over $200 million in funding to accelerate drug development and improve cancer diagnosis.

Focus Areas

Technology Focus

Key People